clinical_trials
A Win for Durvalumab Doublet in Muscle-Invasive Bladder Cancer
Confidence86·multiple reportsImportance88NP-EVT-20261025-6A3BA72
(MedPage Today) -- Perioperative treatment with durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin (EV) significantly improved event-free survival (EFS) and overall survival (OS) compared with radical cystectomy in patients with muscle-invasive...
Read the original at the primary source
A Win for Durvalumab Doublet in Muscle-Invasive Bladder Cancer
10/25/2026, 7:37:39 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —